Lisata Therapeutics

Think Of It As A Guided Missile For Cancer Tumors

About this Event

Lisata Therapeutics’ CendR platform technology uniquely addresses the two challenges that plague the successful treatment of solid tumors, specifically and selectively targeting the tumor and, more importantly, facilitating the penetration of drugs through the harsh protective coating these tumors produce.

Their lead program, LSTA1, uses Lisata’s targeted penetration technology to enhance drug delivery to solid tumors. Basically, LSTA1 acts by selectively initiating at the tumor a naturally occurring molecular transport mechanism which then actively shuttles drugs inside the tumor.

Watch the webinar with Lisata’s President and CEO, David J. Mazzo, PhD, to hear why the FDA has granted Fast Track and Orphan Drug Designations in pancreatic cancer and an Orphan Drug Designation in Glioblastoma.

Hosted by Steven Saltzstein. CEO, Force Family Office

Video On Demand

– Recorded

January 17


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.